Companies /Healthcare

Resmed Inc

NYSE: RMD Medical Instruments & Supplies
$227.10
▼ $5.84 (−2.51%) today
Markets closed · 5:30pm ET

24/7 Wall St. View

RMD at a Glance

Valuation
Market cap
$32.8B
P/E ratio
21.2
Dividend yield
1.07%
Profitability
Revenue (TTM)
$5.7B
Profit margin
27.8%
EPS (TTM)
$10.98
Price
52-week range
$180 – $275
24/7 target
$274.25
Street target
$265.11
Earnings
Next report
Jan 27, 2027

Headquartered in San Diego, CA Fiscal year ends June NYSE: RMD resmed.com

About ResMed

Resmed (NYSE: RMD, ASX: RMD) develops and sells health technologies for sleep and breathing health, serving people in 140 countries. Its Sleep and Breathing Health business sells cloud-connected sleep devices (such as CPAP equipment) and masks and accessories, including the AirTouch line of fabric CPAP masks. It also sells a small and shrinking line of life support devices. Sales are reported across the Americas and Rest of World regions. The company also offers AI-powered digital health solutions and software that support treatment delivered in the patient's home. Its Residential Care Software segment serves out-of-hospital care providers through Brightree and MEDIFOX DAN, following the divestiture of MatrixCare in the September 2026 quarter. Resmed recently acquired Noctrix. It pays a quarterly dividend and repurchases shares. Updated

RMD Coverage

Frequently Asked Questions

What does ResMed do?

Resmed (NYSE: RMD, ASX: RMD) develops and sells health technologies for sleep and breathing health, serving people in 140 countries. Its Sleep and Breathing Health business sells cloud-connected sleep devices (such as CPAP equipment) and masks and accessories, including the AirTouch line of fabric CPAP masks.

What is the RMD stock price target?

24/7 Wall St.'s 12-month price target for RMD is $274.25, rated Buy. The Wall Street consensus target is $265.11. RMD price prediction →